xrcc1g39a单核苷酸多态性与晚期胃癌患者对奥沙利铂化疗敏感性的关系.pdf

摘要 目的：DNA修复能力与肿瘤细胞对铂类药物的敏感性密切相关。本研究旨在探讨DNA 奥沙利铂化疗为主的化疗敏感性的关系。方法：经病理学检查确诊的llI-IV期不能手 技术进行基因分型，探讨接受奥沙利铂化疗病人的基因型与至少2周期化疗的临床 SD)为62％，其中CR2例，PR26例，SD30例，PD36例，G／G野生基因型比含至 (5．3个月)，PO．01。结论：XRCClG399A基因多态性可能与晚期胃癌病人对奥沙 利铂化疗的敏感性及生存时间相关，可作为胃癌病人对奥沙利铂化疗的预测预后指 标之一。 硕士研究生： 姜健(肿瘤学) 指导教师： 梁军教授 铂／化疗 Abstract between OBJECTIVE：Toexaminetheassociation ofXRCCl genetic polymorphisms to ofadvanced Ar9399GIn(GA)andresponseoxaliplatin-basedchemotherapygastric 94 Ill，60 IV)withadvanced cancer．METHODS：Totallystage patients(34stage gastric with cancerweretreated clinical ofallthe oxaliplatin-basedchemotherapy,andresponse wereevaluatedafter2to3 the94 to wereevaluatedtime patients cycles．Alsopatients wereextractedfrom blood 1 before progression(TTP)．DNAperipheral chemotherapy．XRCC weredetected G／G genotypes byTaqMan-MGBprobe 37．24％wereG／A clinicalbenefit genotype，8．50／60were～Agenotype，and genotype．The 62％．Patients埘thG／G showed rate(CR+PR+SD)was genotypedistinctly tothosewithG|时虬入．between preponderance compared response and un—response medianTTPall